BioCryst Pharmaceuticals, Inc.
BioCryst develops oral small-molecule and protein therapeutics for rare diseases. It markets peramivir injection under RAPIVAB, RAPIACTA, and PERAMIFLU names to treat acute uncomplicated influenza. ORLADEYO treats hereditary angioedema. The company also develops BCX10013, an oral factor D inhibitor for complement-mediated diseases. BioCryst has collaborations with various companies and institutions. Founded in 1986, the company is headquartered in Durham, North Carolina.
Overview
Strengths
- Creates economic value: ROIC of 100.0% against a cost of capital (WACC) of 8.0%, a spread of 92.0 percentage points.
- Our discounted cash flow model points to 121% upside (target price 16.96 USD), and even our pessimistic growth scenario implies 90%: a margin of safety.
- Valued below its Drug Manufacturers - Specialty & Generic peers: P/E 6.2x vs. a median of 20.6x, P/FCF 4.8x vs. a median of 21.4x and EV/EBITDA 5.4x vs. a median of 12.9x.
- Consistent growth: revenue has compounded at 117.9% a year over 5 years, rising every year.
- ROIC of 100.0% beats 100% of its 55 Drug Manufacturers - Specialty & Generic peers (median 10.9%).
- EBITDA margin of 41.7% beats 91% of its 55 Drug Manufacturers - Specialty & Generic peers (median 22.4%).
Weaknesses
- Unreliable cash generation: free cash flow was negative in 5 of the last 6 years.
- Unstable profitability: operating margin ranged from -981% to 39% over the last 6 years, with operating losses in 5 of them.
- Shareholder dilution: the share count has grown by 4.3% a year over the last three years.
- Earnings are projected to decline (-10.0% per year).
Key Financial Data